BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Posts Quarterly Earnings Results, Beats Expectations By $0.18 EPS

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) posted its quarterly earnings data on Thursday. The company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.18, Zacks reports.

BridgeBio Oncology Therapeutics Stock Performance

BBOT stock traded up $0.29 during midday trading on Friday, hitting $10.18. 184,452 shares of the stock were exchanged, compared to its average volume of 324,593. The stock has a market cap of $814.29 million, a PE ratio of -9.88 and a beta of 0.28. BridgeBio Oncology Therapeutics has a fifty-two week low of $8.50 and a fifty-two week high of $14.87.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. HC Wainwright raised their target price on shares of BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the stock a “buy” rating in a research note on Friday. Stifel Nicolaus assumed coverage on shares of BridgeBio Oncology Therapeutics in a research report on Tuesday, February 10th. They issued a “buy” rating and a $23.00 price objective for the company. Weiss Ratings assumed coverage on BridgeBio Oncology Therapeutics in a research report on Wednesday, January 14th. They set a “sell (d+)” rating on the stock. Finally, Raymond James Financial raised BridgeBio Oncology Therapeutics to a “moderate buy” rating in a research note on Friday, January 9th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $26.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. CIBC Private Wealth Group LLC purchased a new position in shares of BridgeBio Oncology Therapeutics during the 4th quarter worth approximately $63,000. Persistent Asset Partners Ltd acquired a new stake in shares of BridgeBio Oncology Therapeutics during the fourth quarter valued at $107,000. Squarepoint Ops LLC purchased a new stake in BridgeBio Oncology Therapeutics during the 4th quarter worth about $144,000. Quadrature Capital Ltd purchased a new stake in BridgeBio Oncology Therapeutics during the 4th quarter worth about $162,000. Finally, XTX Topco Ltd raised its stake in BridgeBio Oncology Therapeutics by 22.4% in the 4th quarter. XTX Topco Ltd now owns 28,633 shares of the company’s stock valued at $358,000 after purchasing an additional 5,249 shares during the last quarter. Institutional investors and hedge funds own 54.89% of the company’s stock.

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.